How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)

Your mitochondria are running two separate maintenance systems right now, and most people treating them as the same thing are missing why combining these two peptides actually makes sense.

The first system is structural. Your mitochondria have an inner membrane folded into tight ridges called cristae, and embedded in those folds are the protein complexes that generate ATP. Those complexes are anchored to the membrane by a phospholipid called cardiolipin, which is basically the structural glue that holds everything in position. When cardiolipin gets damaged, the complexes drift apart, electron transfer breaks down, and you get a drop in energy output alongside a spike in something called reactive oxygen species, which are unstable molecules that damage proteins and DNA as a byproduct of inefficient respiration. SS-31 works entirely inside this structural system. It binds directly to cardiolipin and stabilizes the cristae architecture so the complexes stay in the right geometry.

The second system is regulatory. Your mitochondria actually encode a small number of their own signaling molecules, and one of them is MOTS-c, which is a peptide that travels outside the mitochondria and into the nucleus, where it changes which genes are being read. It upregulates pathways that govern how your cells handle glucose, how they clear damaged organelles, and how they respond to metabolic stress. It also activates something called AMPK, which is the master energy sensor your cells use to decide whether to burn or store fuel.

Those two systems do not overlap. SS-31 never touches gene expression. MOTS-c never touches cardiolipin. They are operating on different layers of the same machine, which is the mechanical basis for running them together.

Now the dosing logic for each one follows directly from how each one works.

SS-31 has a plasma half-life of roughly two hours, so it clears from the blood quickly. But the relevant fact is not how long it circulates, it is what happens at the destination. SS-31 concentrates about five thousand fold at the inner mitochondrial membrane compared to plasma levels, so even a small circulating amount delivers a meaningful local concentration. And the effect it produces is structural repair, which accumulates over weeks, not a pharmacological response that peaks and fades with plasma levels. That is why you run it daily. The 168-week Barth syndrome trial from Thompson and colleagues ran SS-31 continuously at 40 milligrams daily, showed progressive improvement throughout, and found no tolerance or diminishing returns at any point. Separately, Butler and colleagues compared 4 milligrams against 40 milligrams in heart failure patients and found the lower dose performed equivalently. The working range for most people is 1 to 5 milligrams per day.

MOTS-c has a different relationship between dose timing and effect. It clears from plasma quickly as well, but its mechanism runs through gene expression, which means the peptide itself does not need to be present for the effect to continue. You are triggering a transcriptional cascade and that cascade keeps running after the signal has cleared. Reynolds and colleagues demonstrated that after a loading phase, dropping to three times per week maintained all of the measured benefits, because you are not sustaining a plasma level, you are periodically re-engaging a signaling pathway that has its own duration. That makes Monday, Wednesday, Friday dosing mechanistically rational rather than just a conservative guess. The weekly total most people work with is 5 to 15 milligrams.

The starting point most people do well at is 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c per week. If you are just beginning, cutting both in half for the first few weeks gives you a reasonable way to gauge your individual response without wasting anything. If you are addressing significant age-related metabolic decline, the upper end of both ranges becomes more appropriate.

On cycling: the standard advice you hear is 8 to 12 weeks on, 4 to 8 weeks off. That advice is probably wrong for these two specifically, and understanding why requires knowing what cycling is actually protecting against.

The reason you cycle most hormonal and pharmacological compounds is receptor desensitization. Your receptors downregulate when they are continuously stimulated, and you lose response. SS-31 does not bind a receptor. It binds cardiolipin, which is a lipid, not a signaling protein. There is no desensitization mechanism. The 168-week continuous trial is not just reassuring data, it is mechanistic confirmation. Something that shows increasing benefit at week 168 is not a compound your body is learning to ignore.

MOTS-c is a peptide your own mitochondria produce endogenously. Unlike testosterone, where exogenous administration suppresses the hypothalamic-pituitary axis through a feedback loop, there is no documented feedback system that downregulates mitochondrial MOTS-c production in response to exogenous MOTS-c. Animal research has shown sustained benefits across the life of the organism with no attenuation. That does not prove the same holds in humans at these doses, and that distinction matters.

The honest position is that the cycling recommendation exists because long-term human data at these dose levels does not exist, not because there is a known mechanism that would require it. The recommendation is precautionary, which is different from being evidence-based.

One more thing to be direct about: no human study has ever combined SS-31 and MOTS-c in the same protocol. The closest published data is a mouse study by Whitson and colleagues that combined SS-31 with NMN, another mitochondrial support compound, and showed synergistic improvement in aged cardiac tissue. That paper is suggestive of combination approaches being viable but it is not the same experiment. The rationale for stacking these two is built on the non-overlapping mechanisms of each and the individual evidence base for each, not on a combined human trial.

The mitochondria are not running on a single system that you either support or you do not. They have a structural layer and a regulatory layer, and ignoring one while addressing the other is leaving half the machinery untouched.

---

References

1. Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
2. Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
3. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
4. Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
5. Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
6. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness